ATE251910T1 - Zusammensetzungen zur modulierung der immunantwort und zur behandlung entzündlicher krankheiten - Google Patents

Zusammensetzungen zur modulierung der immunantwort und zur behandlung entzündlicher krankheiten

Info

Publication number
ATE251910T1
ATE251910T1 AT00932513T AT00932513T ATE251910T1 AT E251910 T1 ATE251910 T1 AT E251910T1 AT 00932513 T AT00932513 T AT 00932513T AT 00932513 T AT00932513 T AT 00932513T AT E251910 T1 ATE251910 T1 AT E251910T1
Authority
AT
Austria
Prior art keywords
compositions
modulating
treating inflammatory
immune response
inflammatory diseases
Prior art date
Application number
AT00932513T
Other languages
English (en)
Inventor
Roger V Kendall
John Lawson
Original Assignee
Foodscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foodscience Corp filed Critical Foodscience Corp
Application granted granted Critical
Publication of ATE251910T1 publication Critical patent/ATE251910T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
AT00932513T 1999-05-21 2000-05-18 Zusammensetzungen zur modulierung der immunantwort und zur behandlung entzündlicher krankheiten ATE251910T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/316,001 US20020018787A1 (en) 1999-05-21 1999-05-21 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
PCT/US2000/013513 WO2000071140A2 (en) 1999-05-21 2000-05-18 Methods and compositions for modulating immune response and for the treatment of inflammatory disease

Publications (1)

Publication Number Publication Date
ATE251910T1 true ATE251910T1 (de) 2003-11-15

Family

ID=23227031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932513T ATE251910T1 (de) 1999-05-21 2000-05-18 Zusammensetzungen zur modulierung der immunantwort und zur behandlung entzündlicher krankheiten

Country Status (11)

Country Link
US (2) US20020018787A1 (de)
EP (1) EP1183037B1 (de)
JP (1) JP2003500362A (de)
AT (1) ATE251910T1 (de)
AU (1) AU777971B2 (de)
CA (1) CA2381441A1 (de)
DE (1) DE60005947T2 (de)
DK (1) DK1183037T3 (de)
ES (1) ES2208330T3 (de)
MX (1) MXPA01011924A (de)
WO (1) WO2000071140A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4545301A (en) * 2000-03-14 2001-09-24 Nat Jewish Med & Res Center Method and composition for treating airway hyperresponsiveness
JP2006520389A (ja) * 2003-03-14 2006-09-07 フードサイエンス、コーポレイション Ｐｅｒｎａｃａｎａｌｉｃｕｌｕｓ成分およびｐｅｒｎａｃａｎａｌｉｃｕｌｕｓエキスを用いる癌の処置方法
WO2008035756A1 (en) * 2006-09-22 2008-03-27 Heimat Co., Ltd. Anti-angiogenic composition comprising extract having anti-angiogenic activity and lecithin
NZ575985A (en) * 2009-03-31 2010-04-30 Bomac Research Ltd Medicament Uptake
RU2705001C2 (ru) 2011-12-22 2019-11-01 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в одногормональные инсулинположительные клетки
WO2017011986A1 (zh) 2015-07-20 2017-01-26 赵兵 一种空气过滤装置
KR102468524B1 (ko) 2015-07-20 2022-11-18 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 멜라닌과 관련된 질환의 치료 및 예방에서의 홍합 접착 단백질 제품의 용도
BR112018000953A2 (pt) * 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
WO2017028025A1 (zh) 2015-08-14 2017-02-23 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制粘膜炎症的应用
WO2017181371A1 (zh) * 2016-04-20 2017-10-26 江阴市本特塞缪森生命科学研究院有限公司 贻贝粘蛋白产品及其抑制脏器炎症的应用
JP7209691B2 (ja) * 2017-07-24 2023-01-20 サミ－サビンサ グループ リミテッド ウコン残渣物、その方法および組成物
EP4129313A3 (de) 2021-08-03 2023-05-10 Theis Theis Cornelsen Pharmazeutische zusammensetzung zur behandlung von neurodermitis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0010061B1 (de) * 1978-09-25 1983-07-13 Stuart John Mc Farlane Einen Mollusken-Extrakt enthaltende pharmazeutische Zusammensetzungen
US4385068A (en) * 1980-03-10 1983-05-24 Davinci Laboratories, A Division Of Food Science Corporation N,N-Dimethylglycine and use in immune response
US4801453A (en) * 1984-05-01 1989-01-31 James M. Broadbent Stabilized mussel extract
US4994492A (en) * 1989-01-09 1991-02-19 Foodscience Corporation Treatment of melanoma using N,N-dimethylglycine
US5118618A (en) * 1989-10-05 1992-06-02 Foodscience Corporation Dimethylglycine enhancement of antibody production
US5026728A (en) * 1989-10-05 1991-06-25 Foodscience Corporation Treatment of arthritis and inflammation using N,N-dimethylglycine
AUPM740594A0 (en) * 1994-08-11 1994-09-01 J.W. Broadbent Nominees Pty. Ltd. Anti-inflammatory preparation
AUPN531195A0 (en) * 1995-09-11 1995-10-05 J.W. Broadbent Nominees Pty. Ltd. Lipid extract having anti-inflamatory activity
US6255295B1 (en) * 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue

Also Published As

Publication number Publication date
EP1183037A2 (de) 2002-03-06
JP2003500362A (ja) 2003-01-07
US20030180288A1 (en) 2003-09-25
US20020018787A1 (en) 2002-02-14
AU5022300A (en) 2000-12-12
WO2000071140A2 (en) 2000-11-30
DE60005947D1 (de) 2003-11-20
DE60005947T2 (de) 2004-07-29
EP1183037B1 (de) 2003-10-15
DK1183037T3 (da) 2004-02-02
MXPA01011924A (es) 2003-09-04
US7229646B2 (en) 2007-06-12
WO2000071140A3 (en) 2001-05-31
AU777971B2 (en) 2004-11-04
ES2208330T3 (es) 2004-06-16
CA2381441A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
ATE519501T1 (de) Rekombinanter anti-cd40 antikörper und dessen anwendungen
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
NO20034056D0 (no) Proliferative sykdommer
DE60005947D1 (de) Zusammensetzungen zur modulierung der immunantwort und zur behandlung entzündlicher krankheiten
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DZ3265A1 (fr) Derives de 4,5-diaryl-3(2h)-furanone comme inhibiteurs de cyclo-oxygenase-2
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
PT902789E (pt) Derivados de androsteno
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
MXPA05010515A (es) Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
ATE469907T1 (de) Triptolid-analoga zur behandlung von autoimmunkranheiten und entzündungen
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE283256T1 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
TR200100637T2 (tr) Yeni doğal ürün türevleri
SE9601395D0 (sv) New therapeutic treatment 1
DE69927260D1 (de) Topische pharmazeutische zusammensetzung zur behandlung von haut- oder zirkulatorischen krankheiten auf inflammatorischer, immun-, proliferativer oder degenerativer basis
ATE375152T1 (de) Behandlung von gastrointestinalen erkrankungen mit n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2- amine
MY135972A (en) Egg anti-inflammatory composition and method of treating and preventing inflammation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties